Showing 361-370 of 4174 results for "".
- Envudeucitinib Improves Itch by Week 2 in Phase 3 Plaque Psoriasis Trialshttps://practicaldermatology.com/news/envudeucitinib-improves-itch-by-week-2-in-phase-3-plaque-psoriasis-trials/2488683/Investigational oral tyrosine kinase 2 (TYK2) inhibitor envudeucitinib produced clinically meaningful itch improvement as early as week 2 in patients with moderate-to-severe plaque psoriasis, according to 24-week results from the phase 3 ONWARD1 and ONWARD2 trials. Jason E. Hawkes, MD, and
- Consensus IDs Gaps in Atopic Dermatitis Skin Modelshttps://practicaldermatology.com/news/consensus-ids-gaps-in-atopic-dermatitis-skin-models/2488670/A 2026 expert consensus review published in the Journal of Investigative Dermatology examined the advantages and limitations of human-based in vitro models for atopic dermatitis (AD), identifying opportunities to improve preclinical research and reduce reliance on animal models. R
- Telehealth Intervention Improves Sun Protection Behaviors in Children of Melanoma Survivorshttps://practicaldermatology.com/news/telehealth-intervention-improves-sun-protection-behaviors-in-children-of-melanoma-survivors/2488649/A family-based telehealth intervention significantly improved sun-protective behaviors among children of melanoma survivors but failed to reduce sunburn over time, according to findings from a randomized study published in JAMA Dermatology. Thye study sought to evaluate whether th
- Environmental Exposures, Skin Barrier Care Take Focus in Pediatric AD Consensushttps://practicaldermatology.com/news/environmental-exposures-skin-barrier-care-take-focus-in-pediatric-ad-consensus/2488624/Environmental exposures early in childhood that affect the skin barrier may contribute to the development of atopic dermatitis, and impact its severity, according to a new expert consensus published in the Journal of Drugs in Dermatology. The SAIGE III report examined current evid
- 2-Year Icotrokinra Data Show Sustained Clearance in High-Impact Psoriasis Siteshttps://practicaldermatology.com/news/2-year-icotrokinra-data-show-sustained-clearance-in-high-impact-psoriasis-sites/2488612/Johnson & Johnson reported 2-year Phase 3 data showing sustained skin clearance with icotrokinra in adults and adolescents aged 12 years or older with plaque psoriasis involving high-impact sites. The late-breaking ICONIC-TOTAL results were presented at the Europ
- Olumiant Gains FDA Approval for Severe Alopecia Areata in Patients 12 and Olderhttps://practicaldermatology.com/news/olumiant-gains-fda-approval-for-severe-alopecia-areata-in-patients-12-and-older/2488595/The FDA has approved Eli Lilly and Company’s Olumiant (baricitinib) for patients aged 12 years and older with severe alopecia areata (AA), expanding the oral Janus kinase (JAK) inhibitor’s US indication to adolescents, according to an announcement from the manufacturer. The
- Biologic Exposure Not Linked to Increased Adverse Pregnancy Outcomes in PsO: Studyhttps://practicaldermatology.com/news/biologic-exposure-not-linked-to-increased-adverse-pregnancy-outcomes-in-psoriasis/2488560/Biologic therapy was not associated with increased adverse pregnancy outcomes among patients with psoriasis in a large real-world cohort study published in the Journal of the American Academy of Dermatology. Investigators compared 1,226 biologic-exposed pregnancies with 1,238 pre
- Expert Consensus Defines Best Practices for Pseudofolliculitis Barbaehttps://practicaldermatology.com/news/expert-consensus-defines-best-practices-for-pseudofolliculitis-barbae/2488539/A new expert consensus study published online in JAMA Dermatology outlines best practices for diagnosing and managing pseudofolliculitis barbae (PFB), including hair removal modification, medical therapy, procedural treatment, and occupational considerations.
- Risankizumab, Ustekinumab Linked to Lower Infection Risk in Psoriasishttps://practicaldermatology.com/news/risankizumab-ustekinumab-linked-to-lower-infection-risk-in-psoriasis/2488488/Biologics and small molecules used in psoriasis therapies had a favorable safety profile, according to new research in the Journal of Investigative Dermatology. Study researchers included 4,820 patients (8,826 treatment cycles; 20,829 patient years of follow-up) in the analysis.
- Dupilumab Shows Sustained Effectiveness Through 3 Years in Pediatric Atopic Dermatitis: Analysishttps://practicaldermatology.com/news/dupilumab-shows-sustained-effectiveness-through-3-years-in-pediatric-atopic-dermatitis-analysis/2488475/Dupilumab demonstrated sustained effectiveness and a 3-year drug survival rate of 80.1% among pediatric patients with moderate to severe atopic dermatitis (AD) in a prospective real-world cohort published in JAMA Derma